Drug Prices
Fifty-seven senators Friday urged the Centers for Medicare & Medicaid Services (CMS) to “carefully consider stakeholder feedback” before the agency finalizes its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. “The long-term success of the…
Once again, the Senate attempted to pass a proposal to repeal and replace significant parts of the Affordable Care Act. Once again, it met defeat – and we are grateful.But this fight is not over. America’s hospitals and health systems must stay vigilant and continue to make the case to protect…
The panel that advises the Centers for Medicare & Medicaid Services on hospital outpatient payments sent a clear signal to the agency this week: Don’t shortchange patients’ access to vital pharmaceuticals by cutting the 340B Drug Pricing Program. CMS’s Advisory Panel on Hospital Outpatient…
The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration’s oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders.
Today, CMS issued several poorly designed policies that will do real damage to patients access to care.
A Senate committee today shined the spotlight on the wave of high and unexpected increases in prescription drug costs that puts an incredible financial strain on hospitals and health systems and threaten our ability to provide high quality care each and every day.
The skyrocketing price of prescription drugs threatens both patient access to care and the ability of providers to deliver the highest quality of care to patients and communities.